Design and characterization of a fluorescent ghrelin analog for imaging the growth hormone secretagogue receptor 1a.
McGirr. Rebecca R; McFarland. Mark S MS; McTavish. Jillian J; Luyt. Leonard G LG; Dhanvantari. Savita S
Key Findings
- A truncated ghrelin peptide (1‑18) linked to FITC binds the GHS‑R1a receptor with affinity similar to wild‑type ghrelin and hexarelin.
- The fluorescent ghrelin analog labels cell‑surface GHS‑R1a, is internalized, and activates downstream ERK1/2 signaling.
- GHS‑R1a protein is highly expressed in the heart, and the probe’s binding to heart tissue can be displaced by ghrelin or hexarelin.
Practical Outcomes
- The study doesn’t provide new dosing guidelines or performance‑enhancing protocols for hexarelin. It mainly offers a new imaging probe that could help researchers study GHS‑R1a distribution and drug interactions, but it has no immediate actionable benefit for self‑directed health optimization.
Summary
Scientists created a glowing version of the hormone ghrelin that sticks to the same receptor that hexarelin targets. It works just as well as natural ghrelin for binding and can be seen inside cells, especially in heart tissue. However, this is a research tool for imaging, not a new supplement or therapy.
Abstract
Ghrelin is a 28-amino acid peptide hormone produced in the stomach. It binds to the growth hormone secretagogue receptor 1a (GHS-R1a), a class A G-protein-coupled receptor. In the present study, we describe the design, synthesis and characterization of a truncated, 18-amino acid analog of ghrelin conjugated to a fluorescent molecule, fluorocein isothiocyanate (FITC), through the addition of a lysine at its C terminus ([Dpr(octanoyl)(3), Lys(fluorescein)(19)]ghrelin(1-19)). Receptor binding affinity of this novel fluorescein-ghrelin(1-18) was similar to that of wild-type ghrelin and a synthetic GHS-R1a ligand, hexarelin. Live cell imaging in CHO/GHS-R1a cells demonstrated cell surface receptor labeling and internalization, and agonist activity of fluorescein-ghrelin(1-18) was confirmed by increased phosphorylation of ERK1/2. We also show that GHS-R1a protein is expressed primarily in the heart when compared to all other organs, suggesting high receptor density in the left ventricle. Finally, we demonstrate that fluorescein-ghrelin(1-18) binds specifically to heart tissue in situ, and its binding is displaced by both wt ghrelin and hexarelin. We have therefore developed a novel imaging probe, fluorescein-ghrelin(1-18), that can be used to image GHS-R1a in situ, for the purposes of investigating mechanisms of receptor trafficking or pharmacological agents that target GHS-R1a.
Study Information
pubmed
2011
2011-09-03T00:00:00.000Z
10.1016/j.regpep.2011.08.011
42
36